Home › Funds › Longaeva Partners L.P. › CYTK
Longaeva Partners L.P. position in CYTK
CYTOKINETICS INC · Health Care
Longaeva Partners L.P. reported holding 361,821 shares of CYTK (CYTOKINETICS INC) in its Q3 2026 13F filing — a position valued at US$23.8M, representing 0.60% of its reported portfolio and ranking #35 among its reported holdings. Longaeva Partners L.P. first reported this position in Q3 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Longaeva Partners L.P.'s CYTK position evolved
Longaeva Partners L.P. first disclosed a stake in CYTK in Q3 2026 at 361,821 shares (US$23.8M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2026 | 361.82K | $23.85M | New |
About CYTK and 13F data
CYTK (CYTOKINETICS INC) is a Health Care company. 36 other funds we track also report a position in CYTK — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.25B), Avoro Capital Advisors LLC (US$323.0M), Polar Capital Holdings Plc (US$227.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CYTK
- T. Rowe Price Investment Management, Inc. 18.91M sh · $1.25B · Q3 2026
- Avoro Capital Advisors LLC 4.90M sh · $322.96M · Q3 2026
- Polar Capital Holdings Plc 9.64M sh · $227.69M · Q3 2026
- RTW INVESTMENTS, LP 2.86M sh · $188.63M · Q3 2026
- ARMISTICE CAPITAL, LLC 1.18M sh · $77.79M · Q3 2026
- Integral Health Asset Management, LLC 1.60M sh · $72.50M · Q3 2026
- GW&K Investment Management, LLC 1.02M sh · $67.08M · Q3 2026
- Royalty Pharma Sub-Manager, LLC 980.39K sh · $64.62M · Q3 2026
- Melqart Asset Management (UK) Ltd 761.54K sh · $50.19M · Q3 2026
- Affinity Asset Advisors, LLC 750.00K sh · $49.43M · Q3 2026
- Foresite Capital Management IV, LLC 714.70K sh · $47.11M · Q3 2026
More on Longaeva Partners L.P.
FAQ
How long has Longaeva Partners L.P. held CYTK?
Longaeva Partners L.P. has disclosed CYTK holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is Longaeva Partners L.P.'s current position in CYTK?
As of Q3 2026, Longaeva Partners L.P. holds 361.82K shares of CYTK (CYTOKINETICS INC), valued at $23.85M, representing 0.60% of its reported portfolio and ranking #35.
Has Longaeva Partners L.P. been buying or selling CYTK?
In the latest 13F filing (Q3 2026), Longaeva Partners L.P. newly opened its position in CYTK.
Which other funds hold CYTK?
Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, Polar Capital Holdings Plc, among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.